0
Deep & Emerging Tech·August 26, 2026·1 min read

Sam Altman's longevity startup is upping the dose in an Alzheimer's drug trial after a lackluster first round

Share

Upping the dose after a weak initial readout is standard biotech iteration, but it underlines how far longevity narratives are from clinical reality in Alzheimer’s. Operators should treat high-profile backers as capital signals, not efficacy proof—wait for phase data before anchoring any strategy on these therapies.

Deep & Emerging Tech

FDA approves world’s first dual-sensor CGM in diabetes 'breakthrough' — new Libre Duo sensor tracks ketones and blood sugar in real-time

A dual-sensor CGM that tracks both glucose and ketones in real time shifts diabetes care toward continuous risk prediction instead of episodic intervention. Healthcare builders should be thinking in terms of longitudinal data products and closed-loop algorithms, not just devices—regulators are now blessing richer, multi-signal wearables.